Compare Adaptive Biotechnologies Corp (ADPT) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while iShares 3 7 Year Treasury Bond ETF trades at $116.61. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | IEI | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Fixed Income |
52-Week High | $22.37 | $120.72 |
52-Week Low | $10.24 | $116.67 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $117.20 with minimal daily movement (+0.08%). Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. The ETF focuses exclusively on intermediate-term U.S. Treasury debt, offering lower volatility compared to corporate bond alternatives. Recent dividend payments of $0.36-$0.37 demonstrate consistent income distribution to investors.
The outlook for IEI remains heavily dependent on Federal Reserve policy direction amid ongoing inflation concerns. While Treasury-focused ETFs provide safety during market volatility, rising rate expectations pose headwinds for bond prices. The fund's government debt exposure offers stability but may underperform higher-yielding alternatives in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
